Introduction: The aim of this paper is to assess the impact of the measures and procedures imposed by the National Medicines and Poisons Board (NMPB) on the availability of safe, effective and quality medicines of affordable price on the Sudanese market. Methods: This is a descriptive study in which pharmacists, who were responsible for the regulatory affairs within their importing and locally manufacturing medicine companies, were asked to complete a 45-question online survey using the Google application, covering relevance and challenges of medicines quality and pricing system. A link to the data collection tool website was sent to all members of the Sudanese Society of Regulatory Affairs Pharmacists through WhatsApp. The survey was available on 6th May 2020 through 6th June 2020. Descriptive statistics were used to report results. Results: Survey respondents were 70 regulatory affairs’ pharmacists. 38% of participants believe that the technical procedures adopted by the NMPB do not achieve the goal of establishing Medicine Regulatory Authorities as described by World Health Organization. Almost all respondents believe that Sudan current economic situation, including the scarcity of foreign currency, has greatly impacted the availability of quality-assured medicines in pharmacies. Participants said that the situation is exacerbated by the intervention of NMPB in determining the exchange rate and controlling the medicine prices. Conclusion: The NMPB should consider options for balancing patient access to quality medicines, and reasonable pricing policies that encourage the local pharmaceutical manufacturing to flourish and a steady flow of quality-assured medicines from abroad to the Sudan market.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was determined to be exempted from review by the institutional review board at the Federal Ministry of Health, Sudan. The General Directorate of Research, Federal Ministry of Health, had reviewed and approved the study protocol.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files